SynthesisBMC cardiovascular disorders2026
The effects of oral magnesium supplements on vascular and endothelial function: an updated systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnesium has been suggested to play a role in cardiovascular health through its effects on endothelial function, vascular stiffness, and blood pressure. This systematic review and meta-analysis aimed to update and evaluate the effect of magnesium supplementation on vascular function and cardiometabolic outcomes in adults.
methodsA systematic search based on PRISMA 2020 guidelines was conducted on PubMed, Web of Science, Scopus, CENTRAL, and ClinicalTrials.gov up to 23 April 2026 to include randomized placebo-controlled trials assessing the effects of magnesium supplementation on flow-mediated dilation (FMD), pulse wave velocity (PWV), and carotid intima-media thickness (CIMT), and as secondary outcomes for serum magnesium levels and systolic and diastolic blood pressure. Random-effect model, subgroup analyses (dose, duration, formulation), meta-regression, sensitivity analyses, and publication bias assessment were performed as well.
resultsA total of twelve randomized controlled trials comprising 389 patients in the magnesium group and 276 patients in the placebo group were included in this study. Magnesium supplementation showed no significant overall effect on FMD (MD = 2.86; 95% CI: - 1.31 to 7.03; p = 0.18). However, doses > 400 mg/day significantly improved FMD (MD = 8.32; 95% CI: 3.45 to 13.19; p < 0.01), but it included 2 studies. CIMT was significantly reduced (MD = - 0.08; 95% CI: - 0.15 to - 0.01; p = 0.03), while PWV showed no significant change (MD = - 0.17; 95% CI: - 0.60 to 0.25; p = 0.43). Serum magnesium increased significantly (MD = 0.05; 95% CI: 0.02 to 0.07; p < 0.01) in overall and in subgroups, whereas blood pressure reductions were not statistically significant (p > 0.3). Meta-regression showed significant modifying effects of higher magnesium doses and higher baseline SBP on FMD, and a significant inverse correlation of baseline body mass index (BMI), baseline PWV, and baseline CIMT on FMD.
conclusionMagnesium supplementation may improve endothelial function and reduce CIMT, particularly at higher doses, although it should be interpreted cautiously because of limited studies and inconsistent effects on arterial stiffness and blood pressure. Further large-scale trials are required to confirm optimal dosing strategies and clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.